You are here: School of Chemistry / Research / Trevor Hambley

Professor Trevor W Hambley, FAA


Contact Details

Professor of Chemistry and Dean of Science
Room 412a
School of Chemistry, Building F11
The University of Sydney, NSW, 2006, Australia
E: trevor.hambley@sydney.edu.au
T: +61 (2) 9351-2830
F: +61 (2) 9351-3329
W: http://sydney.edu.au/science/chemistry/~hamble_t/

Career Profile

  • BSc, Hons I, University of Western Australia
  • PhD, University of Adelaide

Areas of Interest

  • Medicinal inorganic chemistry, in particular, Pt anticancer drugs
  • Investigating the relationship between the reduction potentials of Pt(IV) complexes and their biological activity
  • Investigating methods for controlling the physical and biological properties of platinum(IV) complexes
  • Development of synchrotron radiation based methods for the in situ determination of oxidation states of platinum in biological environments and for reliably determining platinum distributions in these environments
  • Investigation of cobalt complexes as delivery agents for matrix metalloproteinase inhibitors and other anticancer agents
  • Employing XANES technique to determine oxidation states of the cobalt complexes in solution
    Investigating and optimizing anticancer drug uptake in solid tumours and tumour models

Research

Please see our home page for detailed coverage of our research activities.

Publications (2009 to 2013)

  1. Zhang, JZ; Bonnitcha, P; Wexselblatt, E; Klein, AV; Najajreh, Y; Gibson, D and Hambley, TW. Facile preparation of mono-, di- and mixed-carboxylato platinum(IV) complexes for versatile anticancer prodrug design. Chemistry: A European Journal, 19 (5), 1672-1676, 2013. DOI: 10.1002/chem.201203159

  2. Yamamoto, N; Renfrew, AK; Kim, BJ; Bryce, NS and Hambley, TW. Dual targeting of hypoxic and acidic tumor environments with a cobalt(III) chaperone complex. Journal of Medicinal Chemistry, 55 (24), 11013-11021, 2012. DOI: 10.1021/jm3014713

  3. Zhang, JZ; Bryce, NS; Lanzirotti, A; Chen, CKJ; Paterson, D; de Jonge, MD; Howard, DL and Hambley, TW. Getting to the core of platinum drug bio-distributions: the penetration of anti-cancer platinum complexes into spheroid tumour models. Metallomics, 4 (11), 1209-1217, 2012. DOI: 10.1039/c2mt20168b

  4. Failes, TW; Battle, AR; Chen, C; Cullinane, C; Woods, R; Elliott, R; Deacon, GB and Hambley, TW. Structural and anticancer properties of hydrogen bonded diphenyl phosphate adducts of Pt(IV) complexes: The importance of pKa matching. Journal of Inorganic Biochemistry, 115, 220-225, 2012. DOI: 10.1016/j.jinorgbio.2012.04.010

  5. Guo, S-X; Mason, DN; Turland, SA; Lawrenz, ER; Kelly, LC; Fallon, GD; Gatehouse, BM; Bond, AM; Deacon, GB; Battle, AR; hambley, TW; Rainone, S; Webster, LK and Cullinane, C. Systematic differences in electrochemical reduction of the structurally characterized anti-cancer platinum(IV) complexes [Pt{((p-HC6F4)NCH2)2}-(pyridine)2Cl2], [Pt{((p-HC6F4)NCH2)2}(pyridine)2(OH)2], and [Pt{((p-HC6F4)NCH2)2}(pyridine)2(OH)Cl]. Journal of Inorganic Biochemistry, 115, 226-239, 2012. DOI: 10.1016/j.jinorgbio.2012.07.016

  6. Bonnitcha, PD; Kim, BJ; Hocking, RK; Clegg, JK; Turner, P; Neville, SM and Hambley, TW. Cobalt complexes with tripodal ligands: Implications for the design of drug chaperones. Dalton Transactions, 41 (37), 11293-11304, 2012. DOI: 10.1039/c2dt30727h

  7. Zhang, JZ; Bryce, NS; Siegele, R; Carter, EA; Paterson, D; de Jonge, MD; Howard, DL; Ryan, CG and Hambley, TW. The use of spectroscopic imaging and mapping techniques in the characterisation and study of DLD-1 cell spheroid tumour models. Integrative Biology, 4 (9), 1072-1080, 2012. DOI: 10.1039/c2ib20121f

  8. Yamamoto, N; Bryce, NS; Metzler-Nolte, N and Hambley, TW. Effects of enzymatic activation on the distribution of fluorescently tagged MMP-2 cleavable peptides in cancer cells and spheroids. Bioconjugate Chemistry, 23 (6), 1110-1118, 2012. DOI: 10.1021/bc200561n

  9. Hall, MD; Daly, HL; Zhang, JZ; Zhang, M; Alderden, RA; Pursche, D; Foran, GJ and Hambley, TW. Quantitative measurement of the reduction of platinum(IV) complexes using X-ray absorption near-edge spectroscopy (XANES). Metallomics, 4 (6), 568-575, 2012. DOI: 10.1039/c2mt20053h

  10. Zhang, JZ; Wexselblatt, E; Hambley, TW and Gibson, D. Pt(IV) analogs of oxaliplatin that do not follow the expected correlation between electrochemical reduction potential and rate of reduction by ascorbate. Chemical Communcations, 48 (6), 847-849, 2012. DOI: 10.1039/c1cc16647f

  11. Kim, BJ; Hambley, TW and Bryce, NS. Visualising the hypoxia selectivity of cobalt(III) prodrugs. Chemical Science, 2 (11), 2135-2142, 2011. DOI: 10.1039/c1sc00337b

  12. Wolf, SJ; Huynh, T; Bryce, NS; Hambley, TW; Wakelin, LPG; Stewart, BW and Catchpoole, DR. Intracellular trafficking as a determinant of AS-DACA cytotoxicity in rhabdomyosarcoma cells. BMC Cell Biology, 12 (36), 1-12, 2011. DOI: 10.1186/1471-2121-12-36

  13. Norman, JF and Hambley, TW. Targeting strategies for metal-based therapeutics. Book chapter in: Bioinorganic Medicinal Chemistry. ISBN: 978-3-527-32631-0, Editor: Enzo Alessio. Published by Wiley-VCH, Chapter 2, pp. 49-78, 2011.

  14. Yadav, PN; Beveridge, RE; Blay, J; Boyd, AR; Chojnacka, MW; Decken, A; Deshpande, AA; Gardiner, MG; Hambley, TW; Hughes, MJ; Jolly, L; Lavangie, JA; MacInnis, TD; McFarland, SA; New, EJ and Gossage, RA. Platinum-oxazoline complexes as anti-cancer agents: Syntheses, characterisation and initial biological studies. Medicinal Chemistry Communications, 2 (4), 274-277, 2011. DOI: 10.1039/c0md00211a

  15. Daly, HL; Hall, MD; Failes, TW; Zhang, M; Foran, GJ and Hambley, TW. Stabilization of triam(m)inechloridoplatinum complexes by oxidation to PtIV. Australian Journal of Chemistry, 64 (3), 273-278, 2011. DOI: 10.1071/CH11041

  16. Cubo, L; Hambley, TW; Sanz Miguel, PJ; Carnero, A; Navarro-Ranninger, C and Quiroga, AG. The preparation and characterization of trans-platinum(IV) complexes with unusually high cytotoxicity. Dalton Transactions, 40 (2), 344-347, 2011. DOI: 10.1039/c0dt00565g

  17. Ma, Y; Bryce, NS; Whan, RM; Xiao, L; Li, K; Ruys, AJ; Hambley, TW and Boughton, p. Growth of DLD-1 colon cancer cells on Variotis™ scaffolds of controlled porosity: A preliminary study. Journal fo Biomimetics, Biomaterials and Tissue Engineering, 8 (1), 79-89, 2010. DOI: http://dx.doi.org/10.4028/www.scientific.net/JBBTE.8.79

  18. Battle, AR; Bond, AM; Chow, A; Daniels, DP; Deacon, GB; Hambley, TW; Junk, PC; Mason, DN and Wang, J. Syntheses and structures of N-polyfluorophenyl- and N,N'-bis(polyfluorophenyl)ethane-1,2-diaminato(1- or 2-)platinum(II) complexes. Journal of Fluorine Chemistry, 131 (11), 1229-1236, 2010. DOI: 10.1016/j.fluchem.2010.05.011

  19. Bonin, AM; Yáñez, JA; Fukuda, C; Teng, XW; Dillon, DT; Hambley, TW; Lay, PA and Davies, NM. Inhibition of experimental colorectal cancer and reduction in renal and gastrointestinal toxicities by copper-indomethacin in rats. Cancer Chemotherapy and Pharmacology, 66 (4), 755-764, 2010. DOI: 10.1007/s00280-009-1220-5

  20. Clarke, AJ; Yamamoto, N; Jensen, P and Hambley, TW. Iron(III) complexes of fluorescent hydroxamate ligands: Preparation, properties, and cellular processing. Dalton Transactions, (48), 10787-10798, 2009. DOI: 10.1039/b914368h

  21. Klein, AV and Hambley, TW. Platinum drug distribution in cancer cells and tumors. Chem. Rev., 109 (10), 4911-4920, 2009. DOI: 10.1021/cr9001066

  22. New, E; Roche, C; Madawala, R; Zhang, J and Hambley, TW. Fluorescent analogues of quinoline reveal amine ligand loss from cis and trans platinum(II) complexes in cancer cells. Journal of Inorganic Biochemistry, 103 (8), 1120-1125, 2009. DOI: 10.1016/j.jinorgbio.2009.05.005

  23. Diakos, CI; Zhang M; Beale, PJ; Fenton, RR and Hambley, TW. Synthesis, characterisation and in vitro cytotoxicity studies of a series of chiral platinum(II) complexes based on the 2-aminomethylpyrrolidine ligand: X-ray crystal structure of [PtCl2(R-dimepyrr)] (R-dimepyrr = N-dimethyl-2(R)-aminomethylpyrrolidine). European Journal of Medicinal Chemistry, 44 (7), 2807-2814, 2009. DOI: 10.1016/j.ejmech.2008.12.022

  24. Bryce, NS; Zhang, JZ; Whan, RM; Yamamoto, N and Hambley, TW. Accumulation of an anthraquinone and its platinum complexes in cancer cell spheroids: the effect of charge on drug distribution in solid tumour models. Chemical Communications, (19), 2673-2675, 2009. DOI: 10.1039/b902415h

  25. New, EJ; Duan, R; Zhang, JZ and Hambley, TW. Investigations using fluorescent ligands to monitor platinum(IV) reduction and platinum(II) reactions in cancer cells. Dalton Transactions, (16), 3092-3101, 2009. DOI: 10.1039/b821603g

  26. Diakos, CI; Messerle, BA; Murdoch, PDS; Parkinson, JA; Sadler, PJ; Fenton, RR and Hambley, TW. Identification by NMR spectroscopy of the two stereoisomers of the platinum complex [PtCl2(S-ahaz)] (S-ahaz=3(S)-aminohexahydroazepine) bound to a DNA 14-mer oligonucleotide. NMR evidence of structural alteration of a platinated A.T-rich 14-mer DNA duplex. Inorganic Chemistry, 48 (7), 3047-3056, 2009. DOI: 10.1021/ic802207m

  27. Hambley, TW. Is anticancer drug development heading in the right direction? Cancer Research, 69 (4), 1259-1261, 2009. DOI: 10.1158/0008-5472.CAN-08-3786

  28. Hambley, TW. Targeted cancer therapeutics response. Cancer Research, 69 (4), 1267-1267, 2009.

  29. Er, HM and Hambley, TW. Enantioselectivity and stereoselectivity in the reactions of the enantiomers of the platinum complex [PtCl2(ahaz)] (ahaz=3(R)- or 3(S)-aminohexahydroazepine) with DNA. Journal of Inorganic Biochemistry, 103 (2), 168-173, 2009. DOI: 10.1016/j.jinorgbio.2008.09.016

  30. Whan, RM; Messerle, BA and Hambley, TW. Binding of [Pt(1C3)(dien)](2+) to the duplex DNA oligonucleotide 5 '-d(TGGCCA)-3 ': the effect of an appended positive charge on the orientation and location of anthraquinone intercalation. Dalton Transactions, (6), 932-939, 2009. DOI: 10.1039/b814604g